[多组组合测试对高风险肝癌患者群体机会性查的有效性]
1Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
概括
一种新的多组测试,HCCscreen,在高风险人群中显示出对早期肝癌检测的高灵敏度. 这种先进的查工具的性能优于传统的方法,如α-fetoprotein (AFP) 和超声波.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 在瘤学瘤学.
- 分子诊断学 分子诊断
背景情况:
- 在高风险人群中早期发现肝癌对于改善患者的治疗结果至关重要.
- 目前的查方法,包括α-fetoprotein (AFP) 和B-超声波,在灵敏度和特异性方面存在局限性.
- 需要更有效的查工具来识别肝癌和癌前疾病的个体.
研究的目的:
- 为了验证早期肝癌查的多奥米克组合测试 (HCCscreen) 的现实世界性能.
- 为了比较HCCscreen与传统查方法 (AFP,B-超声波) 的疗效.
- 评估多种病菌标志物与疾病严重程度之间的相关性.
主要方法:
- 预期对164名高风险肝癌患者进行查.
- 采用了多组组测试,结合了基因甲基化,TP53 / TERT / CTNNB1突变,AFP和PIVKA-II.
- 统计分析包括千平方测试,费舍尔的精确测试和曼-惠特尼U测试.
主要成果:
- HCCscreen实现了100%的肝癌敏感度和93.8%的癌症前癌症肝癌敏感度.
- 与AFP (AUC=0.78) 和AFP+B超声波 (AUC=0.86) 相比,多奥米克试验显示出更高的性能 (AUC=0.84).
- 查显示与甲基化+突变得分有显著的线性相关性 (r=0.73,P<0.001).
结论:
- HCCscreen是一种高度敏感和有效的工具,用于在现实环境中早期查肝癌.
- 与现有方法相比,多omics方法显示出对肝癌和癌前疾病的更高检测潜力.
- HCCscreen为高风险肝癌患者群体的查策略提供了有前途的进展.
更多相关视频
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.7K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.5K
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...